Last Updated : Wednesday, January 15, 2020 14:14:31

SUN PHARMA inks pact to commercialize haemoglobin maintenance drug

MUMBAI | RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Mumbai headquartered Indian Pharma Major – Sun Pharmaceuticals Ltd said of having inked licensing agreement with US based Rockwell Medical, for commercializing Triferic, a drug used for iron replacement and haemoglobin maintenance, for treating anaemia in hemodialysis patients in India.

The release titled, “Sun Pharma and Rockwell Medical enter into licensing agreement for Triferic in India”, further read that, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has entered into exclusive licensing and supply agreements with Rockwell Medical Inc. (Rockwell), to commercialize Rockwell’s Triferic, a proprietary iron replacement and haemoglobin maintenance drug, for treating anaemia in hemodialysis patients in India.

Triferic  is approved in USA.

As per the terms of the agreement, Sun Pharma will be the exclusive development and commercialization partner for Triferic during the term of the agreement, subject to its approval in India.

In consideration for the license, Rockwell will be eligible for upfront and milestone payments as well as royalty on net sales.

The financial terms of the agreement are confidential.

According to the 2017 Global Burden of Disease Study, chronic kidney disease was the 10th leading cause of mortality in India, having risen from 14th rank in 20071.

In India, there are approximately 130,000 patients receiving hemodialysis, and the number is increasing by about 232 per million population.

To read more, please CLICK here.


FacebookGoogle+LinkedinTwitterYouTube, Blogspot, Telegram, Instagram 


Do NOT follow this link or you will be banned from the site!